Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors

Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors

BackgroundImmune checkpoint inhibitor (ICI) therapy has improved survivals with a favorable toxicity profile in a variety of cancer patients. We hypothesized that hospitalized cancer patients who have acute or chronic comorbidities may have suppressed immune systems and poor clinical outcomes to ICI...

Full description

Bibliographic Details
Main Authors: Richard Benjamin Young, Hemali Panchal, Weijie Ma, Shuai Chen, Aaron Steele, Andrea Iannucci, Tianhong Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitor (ICI)
inpatient
survival outcome
comorbidities
absolute lymphocyte count (ALC)
derived neutrophil to lymphocyte ratio (dNLR)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.980181/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.980181/full

Similar Items